By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Octreotide (monograph) > Octreotide Dosage
Drugs
https://themeditary.com/dosage-information/octreotide-dosage-12301.html

Octreotide Dosage

Drug Detail:Octreotide (monograph) (Sandostatin)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Carcinoid Tumor

Initial dose: 100 to 600 mcg per day, IV or subcutaneously, in 2 to 4 divided doses

Comments:

  • The median daily dose was 450 mcg; mean daily dose was 300 mcg.
  • Benefits were seen in doses from 50 mcg to 1500 mcg per day.
  • Experience with doses above 750 mcg per day is limited.


Long-Acting depot formulation (Establish tolerability with short acting product for at least 2 weeks before using this formulation):
Initial dose: 20 mg, IM (intragluteally), at 4 week intervals, for 2 months; continue with dose of regular octreotide for at least 2 weeks (at same dose patient was on before the switch)
After 2 months:
  • If symptoms are controlled, consider reducing dose to 10 mg every 4 weeks
  • If symptoms are not adequately controlled, increase to 30 mg every 4 weeks
Maximum dose: 30 mg every 4 weeks

Comments:
  • Failure to continue dosing of regular octreotide during a switch to the long acting formulation may exacerbate symptoms; some patients require 3 to 4 weeks of concomitant dosing.

Use: Symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease.

Usual Adult Dose for Vasoactive Intestinal Peptide Tumor

Initial dose: 200 to 300 mcg per day, IV or subcutaneously, in 2 to 4 divided doses
Maintenance dose: 150 to 750 mcg per day

  • Doses above 450 mcg per day are not usually required.


Long-Acting depot formulation (Establish tolerability with short acting product for at least 2 weeks before using this formulation):
Initial dose: 20 mg, IM (intragluteally), at 4 week intervals, for 2 months; continue with dose of regular octreotide for at least 2 weeks (at same dose patient was on before the switch)
After 2 months:
  • If symptoms are controlled, consider reducing dose to 10 mg every 4 weeks
  • If symptoms are not adequately controlled, increase to 30 mg every 4 weeks

Comments:
  • Adjust dose for therapeutic response.

Use: Long term treatment of the profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.

Usual Adult Dose for Acromegaly

Initial dose: 50 mcg, IV or subcutaneously, 3 times a day
Maintenance dose: Usually 100 mcg, 3 times a day
Maximum dose: 500 mcg, 3 times a day

Comments:

  • Starting at a low dose may help patients adapt to gastrointestinal adverse events.
  • Use IGF-1 (somatomedin C) levels, every 2 weeks, to guide titration.
  • Multiple growth hormone levels, zero to 8 hours after dosing, may permit more rapid dose titration.
  • Doses over 300 mcg per day seldom provide additional biochemical benefit.


Long-Acting depot formulation (Establish tolerability with short acting product for at least 2 weeks before using this formulation):
Initial dose: 20 mg, IM (intragluteally), at 4 week intervals, for 3 months
After 3 months:
  • If GH is 1 ng/mL or less, IGF-1 normal, and clinical symptoms controlled: 10 mg, IM, every 4 weeks
  • If GH is 2.5 ng/mL or less and clinical symptoms controlled: 20 mg, IM, every 4 weeks
  • If GH is higher than 2.5 ng/mL and/or clinical symptoms uncontrolled: 30 mg, IM, every 4 weeks
  • If GH, IGF-1, or symptoms are not adequately controlled at 30 mg, may increase dose to 40 mg IM every 4 weeks
Maximum dose: 40 mg, every 4 weeks

Delayed release oral capsules:
Initial dose: 20 mg orally twice daily, at least 1 hour before or 2 hours after a meal
Maximum dose: 80 mg per day
  • Titrate dose in increments of 20 mg daily based on IGF-1 levels and patient symptoms.
  • Total daily doses of 60 mg should be given as 40 mg in the morning and 20 mg in the evening
  • Total daily doses of 80 mg should be given as 40 mg twice daily.


Comments:
  • The goal is growth hormone (GH) levels under 5 ng/mL, or IGF-1 levels under 1.9 U/mL (male) or 2.2 U/mL (female).
  • If increased doses do not provide additional benefit, reduce dose.
  • Check IGF-1 or growth hormone levels every 6 months.
  • For patients who have received irradiation: withdraw medication yearly for about 4 weeks (8 weeks for long-acting formulation) to assess disease activity; if growth hormone or IGF-1 increase and symptoms recur, resume therapy.

Use: To reduce blood levels of growth hormone and IGF-1 (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection or radiotherapy.

Renal Dose Adjustments

Injectable formulations: No adjustment recommended.

Delayed release oral capsules:
End stage renal disease: Initiate dose at 20 mg orally once daily

  • Titrate dose based on IGF-1 levels, patient symptoms, and tolerability.

Liver Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution is recommended.

Long acting formulation: For cirrhotic patients, starting dose is 10 mg every 4 weeks; titrate up based on clinical response.

Dose Adjustments

Long-acting depot formulation:
Carcinoid tumor and Vasoactive Intestinal Peptide Tumor patients:

  • Exacerbation of symptoms is common.
  • During exacerbations, administer regular octreotide at dose they were previously receiving (before switching to long acting) for a few days.


Delayed release oral capsules: Concomitant proton pump inhibitor, H2-receptor antagonist, or antacid use may require increased octreotide doses.

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.
This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution is recommended.

Long acting depot formulation: Starting dose is 10 mg every 4 weeks

Other Comments

Administration advice:

  • Standard formulation may be given IV or subcutaneously.
  • Subcutaneous route is usually used for control of symptoms.
  • To minimize pain with subcutaneous administration, use smallest volume that will deliver the dose.
  • Avoid multiple subcutaneous injections at the same site within a short period of time.
  • Rotate sites systematically.
  • Infuse IV over 15 to 30 minutes
  • Administer IV push over 3 minutes
  • Rapid bolus may be given for emergency situations.
  • Delayed release capsules should be taken on an empty stomach (1 hour before or 2 hours after a meal).
  • Swallow delayed release capsules whole; do not crush or chew capsules.

Storage requirements:
  • Refrigerate; protect from light
  • Stable for 14 days at room temperature (70 to 86F) if protected from light

Reconstitution/preparation techniques:
  • Dilute in 50 to 200 mL for IV infusion

IV compatibility:
  • Stable in sterile isotonic saline solutions or dextrose 5% in water (D5W) for 24 hours.
  • NOT compatible with TPN (total parenteral nutrition).

Monitoring:
  • Monitor IGF-1 (somatomedin C) or growth hormone levels every 6 months.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by